THRX Theseus Pharmaceuticals Inc

-0.0395 (-1.45%)
Last Updated: 12:59:23
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 57,878
Bid Price 2.68
Ask Price 2.70
News -
Day High 2.76


52 Week Range


Day Low 2.653
Company Name Stock Ticker Symbol Market Type
Theseus Pharmaceuticals Inc THRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0395 -1.45% 2.6805 12:59:23
Open Price Low Price High Price Close Price Prev Close
2.75 2.653 2.76 2.72
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
485 57,878 $ 2.70 $ 156,058 - 2.62 - 14.7672
Last Trade Time Type Quantity Stock Price Currency
13:05:50 2 $ 2.70 USD

Theseus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
116.88M 43.60M - 0 -50.61M -1.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Theseus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No THRX Message Board. Create One! See More Posts on THRX Message Board See More Message Board Posts

Historical THRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.862.932.6532.7893,794-0.1795-6.28%
1 Month3.163.282.6532.9490,422-0.4795-15.17%
3 Months9.2810.262.623.69685,916-6.60-71.12%
6 Months7.3912.372.624.89405,576-4.71-63.73%
1 Year5.8014.76722.626.15293,651-3.12-53.78%
3 Years20.8024.542.628.02216,066-18.12-87.11%
5 Years20.8024.542.628.02216,066-18.12-87.11%

Theseus Pharmaceuticals Description

Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.